EMA — authorised 7 December 2011
- Application: EMEA/H/C/002293
- Marketing authorisation holder: Takeda Pharma A/S
- Local brand name: Edarbi
- Indication: Edarbi is indicated for the treatment of essential hypertension in adults.
- Status: approved
🇪🇺 TAK-491 in European Union
EMA authorised TAK-491 on 7 December 2011
Marketing authorisations
EMA — authorised 7 December 2011
- Application: EMEA/H/C/002517
- Marketing authorisation holder: Takeda Pharma A/S
- Local brand name: Ipreziv
- Indication: Ipreziv is indicated for the treatment of essential hypertension in adults.
- Status: withdrawn
Frequently asked questions
Is TAK-491 approved in European Union?
Yes. EMA authorised it on 7 December 2011; EMA authorised it on 7 December 2011.
Who is the marketing authorisation holder for TAK-491 in European Union?
Takeda Pharma A/S holds the EU marketing authorisation.